Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  ACS Chemical Neuroscience

• Publication date

  2010-02-17

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/CN900003HPMID 21961051PMCID PMC3180826
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins.

  2009cited by this paper
• Discovery and Characterization of Novel Allosteric Potentiators of M1 Muscarinic Receptors Reveals Multiple Modes of Activity

  2009cited by this paper
• Mutagenic Mapping Suggests a Novel Binding Mode for Selective Agonists of M1 Muscarinic Acetylcholine Receptors

  2009cited by this paper
• Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders

  2009cited by this paper
• A Novel Selective Muscarinic Acetylcholine Receptor Subtype 1 Antagonist Reduces Seizures without Impairing Hippocampus-Dependent Learning

  2009cited by this paper
• Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.

  2009cited by this paper
• Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists.

  2009cited by this paper
• Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77‐LH‐28‐1

  2008cited by this paper
• Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats

  2008cited by this paper
• Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats

  2008cited by this paper
• An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission.

  2008cited by this paper
• Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia

  2008cited by this paper
• Layer 2/3 synapses in monocular and binocular regions of tree shrew visual cortex express mAChR-dependent long-term depression and long-term potentiation.

  2008cited by this paper
• Application of combinatorial chemistry science on modern drug discovery.

  2008cited by this paper
• Allosteric modulation of kinases and GPCRs: design principles and structural diversity.

  2008cited by this paper
• Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.

  2008cited by this paper
• G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms.

  2008cited by this paper
• Muscarinic acetylcholine receptors as CNS drug targets.

  2008cited by this paper
• M1 Muscarinic Agonists Target Major Hallmarks of Alzheimer’s Disease – The Pivotal Role of Brain M1 Receptors

  2008cited by this paper
• Muscarinic acetylcholine receptor status in Alzheimer’s disease assessed using (R, R) 123I-QNB SPECT

  2007cited by this paper
• High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.

  2007cited by this paper
• Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia.

  2007cited by this paper
• Towards a muscarinic hypothesis of schizophrenia

  2007cited by this paper
• Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development

  2007cited by this paper
• Current pharmacotherapy for Alzheimer's disease.

  2006cited by this paper
• Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder

  2006influential reference
• ROSETTALIGAND: Protein–small molecule docking with full side‐chain flexibility

  2006cited by this paper
• Muscarinic acetylcholine receptor knockout mice show distinct synaptic plasticity impairments in the visual cortex

  2006cited by this paper
• Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.

  2006cited by this paper
• Current Pharmacotherapy for Alzheimer ’ s Disease

  2006cited by this paper
• M1 receptors play a central role in modulating AD-like pathology in transgenic mice.

  2006cited by this paper
• Probing the Molecular Mechanism of Interaction between 4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the Muscarinic M1 Receptor: Direct Pharmacological Evidence That AC-42 Is an Allosteric Agonist

  2006cited by this paper
• Modulation of Synaptic Plasticity by Physiological Activation of M1 Muscarinic Acetylcholine Receptors in the Mouse Hippocampus

  2005cited by this paper
• Acetylcholinesterase inhibition in Alzheimer's Disease.

  2004cited by this paper
• LTP and LTD: an embarrassment of riches.

  2004cited by this paper
• Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus.

  2004cited by this paper
• Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice

  2003cited by this paper
• N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity

  2003cited by this paper
• Discovery of an ectopic activation site on the M(1) muscarinic receptor.

  2002cited by this paper
• Elucidating the role of muscarinic receptors in psychosis.

  2001cited by this paper
• On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis.

  2000cited by this paper
• Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells.

  1998cited by this paper
• Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

  1997cited by this paper
• Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain.

  1993cited by this paper
• An Embarrassment of Riches

  1992cited by this paper

• Allosteric modulation of M1 or M4 muscarinic receptors restores eNOS expression and L-arginine metabolism in dementia models and synergizes with NO releasers.

  2025cites this paper
• G protein-coupled receptors: A golden key to the treasure-trove of neurodegenerative diseases.

  2025cites this paper
• Co-stimulation of muscarinic M1 and M4 acetylcholine receptors prevents later cocaine reinforcement in male and female mice, but not place-conditioning.

  2024cites this paper
• M1/M4 receptors as potential therapeutic treatments for schizophrenia: A comprehensive study.

  2024cites this paper
• Discovery of VU0467319: an M1 Positive Allosteric Modulator Candidate That Advanced into Clinical Trials

  2024cites this paper
• A golden age of muscarinic acetylcholine receptor modulation in neurological diseases

  2024cites this paper
• Preclinical evaluation of [18F]SYN1 and [18F]SYN2, novel radiotracers for PET myocardial perfusion imaging

  2024cites this paper
• Differential pharmacological and sex-specific effects of antimuscarinic agents at the hypoglossal motor nucleus in vivo in rats

  2022cites this paper
• CalDAG-GEFI mediates striatal cholinergic modulation of dendritic excitability, synaptic plasticity and psychomotor behaviors

  2021cites this paper
• Serotonergic–Muscarinic Interaction within the Prefrontal Cortex as a Novel Target to Reverse Schizophrenia-Related Cognitive Symptoms

  2021cites this paper
• Functionally selective and biased agonists of muscarinic receptors.

  2021cites this paper
• Bitopic Sigma 1 Receptor Modulators to Shed Light on Molecular Mechanisms Underpinning Ligand Binding and Receptor Oligomerization.

  2021cites this paper
• Neuromodulation of Persistent Activity and Working Memory Circuitry in Primate Prefrontal Cortex by Muscarinic Receptors

  2021influential citation
• M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?

  2020cites this paper
• Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders.

  2019cites this paper
• Effects of novel hexahydropyrimidine derivatives as potential ligands of M1 muscarinic acetylcholine receptor on cognitive function, hypoxia-induced lethality, and oxidative stress in rodents.

  2019cites this paper
• Allosteric Modulators of Potential Targets Related to Alzheimer's Disease: a Review

  2019cites this paper
• Retrograde activation of CB1R by muscarinic receptors protects against central organophosphorus toxicity.

  2019cites this paper
• Muscarinic agonist, (±)-quinuclidin-3-yl-(4-fluorophenethyl)(phenyl)carbamate: High affinity, but low subtype selectivity for human M1 - M5 muscarinic acetylcholine receptors.

  2019cites this paper
• Simultaneous activation of muscarinic and GABAB receptors as a bidirectional target for novel antipsychotics

  2019cites this paper
• A second for the cholinergic system in Alzheimer therapy

  2019cites this paper
• Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

  2019cites this paper
• Simultaneous activation of mGlu2 and muscarinic receptors reverses MK-801-induced cognitive decline in rodents.

  2019cites this paper
• PKC and Ras are Involved in M1 Muscarinic Receptor-Mediated Modulation of AMPA Receptor GluA1 Subunit

  2019cites this paper
• Verapamil attenuates scopolamine induced cognitive deficits by averting oxidative stress and mitochondrial injury – A potential therapeutic agent for Alzheimer’s Disease

  2019cites this paper
• Mutations in CalDAG-GEFI Lead to Striatal Signaling Deficits and Psychomotor Symptoms in Multiple Species Including Human

  2019cites this paper
• Effects of muscarinic M1 and M4 acetylcholine receptor stimulation on extinction and reinstatement of cocaine seeking in male mice, independent of extinction learning

  2018cites this paper
• Hippocampal place cell dysfunction and the effects of muscarinic M1 receptor agonism in a rat model of Alzheimer's disease

  2018cites this paper
• Cognitive enhancement and antipsychotic‐like activity following repeated dosing with the selective M4 PAM VU0467154

  2018cites this paper
• Optical functionalization of human Class A orphan G-protein-coupled receptors

  2018cites this paper
• Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry.

  2017cites this paper
• Disease-Modifying Effects of M1 Muscarinic Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model.

  2017cites this paper
• A second wind for the cholinergic system in Alzheimer’s therapy

  2017cites this paper
• Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs.

  2017cites this paper
• Identification and in vivo Characterization of a Potential TAAR1 Antagonist

  2017cites this paper
• Molecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor.

  2017cites this paper
• Acetylcholine Receptor Muscarinic 1 Modulation at the M Molecular Determinants of Allosteric Signal Transduction

  2016cites this paper
• Effects of Selective M1 Muscarinic Receptor Activation on Hippocampal Spatial Representations and Neuronal Oscillations.

  2016cites this paper
• Metabotropic glutamate receptors as targets for new antipsychotic drugs: Historical perspective and critical comparative assessment.

  2016cites this paper
• Abdul-Ridha, Alaa and Lane, J. Robert and Mistry, Shailesh N. and Lopez, Laura and Sexton, Patrick M. and Scammells, Peter J. and Christopoulos, Arthur and Canals, Meritxell (2014) Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine

  2016cites this paper
• Protection Efficacy of the Extract of Ginkgo biloba against the Learning and Memory Damage of Rats under Repeated High Sustained +Gz Exposure

  2016cites this paper
• Allosteric Modulation of Muscarinic Receptors

  2016cites this paper
• Cognition Enhancing and Neuromodulatory Propensity of Bacopa monniera Extract Against Scopolamine Induced Cognitive Impairments in Rat Hippocampus

  2016cites this paper
• Data regarding M1 muscarinic receptor-mediated modulation of hepatic catalase activity in response to oxidative stress

  2015influential citation
• The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model.

  2015cites this paper
• The muscarinic system, cognition and schizophrenia.

  2015cites this paper
• Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents.

  2015cites this paper
• Discovery of dihydroquinazolinone derivatives as potent, selective, and CNS-penetrant M(1) and M(4) muscarinic acetylcholine receptors agonists.

  2015cites this paper
• Outline of therapeutic interventions with muscarinic receptor-mediated transmission.

  2014cites this paper
• Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders

  2014cites this paper
• Effects of Selective Activation of M1 and M4 Muscarinic Receptors on Object Recognition Memory Performance in Rats

  2014cites this paper
• 2013 Philip S. Portoghese Medicinal Chemistry Lectureship: Drug Discovery Targeting Allosteric Sites

  2014cites this paper
• Development of allosteric modulators of GPCRs for treatment of CNS disorders.

  2014cites this paper
• M1 muscarinic acetylcholine receptor in Alzheimer’s disease

  2014cites this paper
• Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia

  2014cites this paper
• Selective Activation of M4 Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents

  2014cites this paper
• Discovery of N-substituted 7-azaindoline derivatives as potent, orally available M1 and M4 muscarinic acetylcholine receptors selective agonists.

  2014cites this paper
• Molecular Mechanisms of Bitopic Ligand Engagement with the M1 Muscarinic Acetylcholine Receptor*

  2014cites this paper
• Mechanistic Insights into Allosteric Structure-Function Relationships at the M1 Muscarinic Acetylcholine Receptor*

  2014cites this paper
• Molecular Determinants of Allosteric Modulation at the M1 Muscarinic Acetylcholine Receptor*

  2014cites this paper
• Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100

  2014cites this paper
• Scopolamine Reduces the Density of M 1 Muscarinic Neurons in Rats ' Hippocampus

  2014cites this paper
• Muscarinic Acetylcholine Receptor Activators

  2014cites this paper
• Muscarinic Acetylcholine Receptor 1 Structure-Function Relationships at the M Mechanistic Insights into Allosteric

  2014cites this paper
• Activation of M 1 and M 4 muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia

  2014cites this paper
• Classics in chemical neuroscience: clozapine.

  2013cites this paper
• Allosteric modulation of the M 1 muscarinic acetylcholine receptor : improving cognition and a potential treatment for schizophrenia and Alzheimer ’ s disease

  2013cites this paper
• Reverse Engineering of the Selective Agonist TBPB Unveils Both Orthosteric and Allosteric Modes of Action at the M1 Muscarinic Acetylcholine Receptor

  2013influential citation
• Scopolamine reduces the density of M1 muscarinic neurons in rats' hippocampus

  2013cites this paper
• Pharmacological characterization of M1 muscarinic acetylcholine receptor-mediated Gq activation in rat cerebral cortical and hippocampal membranes

  2013cites this paper
• DOS‐Derived Small‐Molecule Probes in Chemical Biology

  2013cites this paper
• Neuromodulatory Propensity of Bacopa monniera Against Scopolamine-Induced Cytotoxicity in PC12 Cells Via Down-Regulation of AChE and Up-Regulation of BDNF and Muscarnic-1 Receptor Expression

  2013cites this paper
• Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism.

  2013cites this paper
• Sphingosine-1-phosphate and its receptors: structure, signaling, and influence.

  2013cites this paper
• Discovery of novel N-substituted oxindoles as selective m1 and m4 muscarinic acetylcholine receptors partial agonists.

  2013cites this paper
• Identification of N-substituted 8-azatetrahydroquinolone derivatives as selective and orally active M(1) and M(4) muscarinic acetylcholine receptors agonists.

  2013cites this paper
• Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.

  2013cites this paper
• Effects of selective allosteric activation of M 1 and M 4 muscarinic receptors on object recognition memory performance in rats

  2013cites this paper
• Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.

  2013influential citation
• Fluorescent derivatives of AC-42 to probe bitopic orthosteric/allosteric binding mechanisms on muscarinic M1 receptors.

  2012cites this paper
• M1 muscarinic cetylcholine receptor allosteric modulators as potential therapeutic opportunities for treating Alzheimer's disease

  2012cites this paper
• Muscarinic receptor pharmacology and circuitry for the modulation of cognition.

  2012cites this paper
• Cognitive Enhancers (Nootropics). Part 1: Drugs Interacting with Receptors

  2012cites this paper
• Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169.

  2012cites this paper
• Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor.

  2012cites this paper
• Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia

  2012influential citation
• Muscarinic antagonist control of myopia: evidence for M4 and M1 receptor-based pathways in the inhibition of experimentally-induced axial myopia in the tree shrew.

  2012cites this paper
• Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

  2012cites this paper
• Synthesis and Biological Evaluation of Cremastrine and an Unnatural Analogue.

  2012cites this paper
• Contribution of both M1 and M4 receptors to muscarinic agonist-mediated attenuation of the cocaine discriminative stimulus in mice

  2012influential citation
• The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque

  2012cites this paper
• Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease.

  2012cites this paper
• Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode.

  2012cites this paper
• Novel Allosteric Agonists of M1 Muscarinic Acetylcholine Receptors Induce Brain Region-Specific Responses That Correspond with Behavioral Effects in Animal Models

  2012influential citation
• Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential.

  2011cites this paper
• Identification and role of muscarinic receptor subtypes expressed in rat adrenal medullary cells.

  2011cites this paper
• Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe.

  2011cites this paper
• Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071.

  2011cites this paper
• Alzheimer's disease: emerging trends in small molecule therapies.

  2011cites this paper
• Targeting glutamate synapses in schizophrenia.

  2011cites this paper